| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse Mouse immunoglobulin |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL12A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL12A抗体的3篇参考文献的简要信息(注：内容为模拟示例，非真实文献)：
1. **"Structural insights into IL12A antibody neutralization mechanism"**
- 作者：Smith A, et al.
- 摘要：通过X射线晶体学解析了靶向IL12A的单克隆抗体(如ustekinumab)与其抗原的结合表位，揭示了抗体阻断IL12/IL23受体信号通路的分子机制。
2. **"Anti-IL12A antibody therapy ameliorates experimental autoimmune encephalomyelitis"**
- 作者：Chen L, et al.
- 摘要：在小鼠多发性硬化模型中，抗IL12A抗体通过抑制Th1和Th17细胞分化，显著减轻中枢神经系统炎症和脱髓鞘病变，提示其在自身免疫病中的治疗潜力。
3. **"Development of a high-affinity humanized IL12A antibody for cancer immunotherapy"**
- 作者：Wang Y, et al.
- 摘要：报道了一种人源化抗IL12A抗体的工程化优化过程，该抗体在黑色素瘤模型中增强T细胞抗肿瘤活性，并与PD-1抑制剂表现出协同效应。
注：如需真实文献，建议在PubMed或Google Scholar中检索关键词“IL12A antibody”、“anti-IL12A therapeutic”等，并筛选近5年高被引研究。
**Background of IL12A Antibodies**
IL12A antibodies target the interleukin-12 subunit alpha (IL12A), a key component of the pro-inflammatory cytokine IL-12. IL-12 is a heterodimer composed of IL12A (p35) and IL12B (p40), produced primarily by antigen-presenting cells like dendritic cells and macrophages. It plays a critical role in bridging innate and adaptive immunity by promoting Th1 cell differentiation, enhancing IFN-γ production, and driving anti-tumor and anti-infectious responses.
Antibodies against IL12A are designed to specifically block the p35 subunit, thereby inhibiting IL-12 signaling. This pathway is implicated in autoimmune diseases (e.g., psoriasis, inflammatory bowel disease) and chronic inflammatory conditions, where IL-12 overexpression contributes to pathological inflammation. Early therapeutic strategies targeting IL-12/IL-23 pathways used anti-p40 antibodies (shared by IL-12 and IL-23), but IL12A-specific antibodies offer a more selective approach to modulate IL-12 without affecting IL-23. potentially reducing off-target effects.
IL12A antibodies are also vital research tools for detecting IL-12 expression in immunoassays (ELISA, flow cytometry) and studying its biological functions in vitro and in vivo. Structural studies reveal IL12A’s conserved immunoglobulin-like domain with intrachain disulfide bonds, informing antibody design. Despite therapeutic potential, challenges include balancing efficacy with safety, as broad IL-12 suppression may impair host defense. Ongoing research focuses on optimizing IL12A-targeted biologics for precision immunotherapy.
×
